EID1抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P08269(EID1 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P08269(EID1 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

EID1 (E1A-like inhibitor of differentiation 1) is a transcriptional regulatory protein initially identified for its role in repressing cellular differentiation by interfering with transcriptional coactivators. It belongs to the EID family and functions as a corepressor by binding to CREB-binding protein (CBP)/p300. histone acetyltransferases critical for chromatin remodeling and gene activation. EID1 contains an LXCXE motif, enabling interaction with retinoblastoma (pRb) tumor suppressor proteins, and a C-terminal domain that inhibits CBP/p300’s histone acetyltransferase (HAT) activity. This inhibition disrupts transcriptional complexes, particularly those involving MyoD and other differentiation-promoting factors, thereby maintaining cells in an undifferentiated state.

EID1 is implicated in cell cycle regulation, apoptosis, and tumorigenesis, with overexpression observed in certain cancers. Its antibody is widely used in research to study mechanisms of transcriptional repression, epigenetic regulation, and cellular differentiation pathways. In experimental settings, EID1 antibodies facilitate detection via Western blot, immunofluorescence, or chromatin immunoprecipitation (ChIP), aiding investigations into its role in development, stem cell biology, and cancer progression. Recent studies also explore its involvement in neurological processes and crosstalk with signaling pathways like Notch and Wnt. The antibody’s specificity and reliability make it a key tool for dissecting EID1’s dual roles as a differentiation suppressor and potential oncogenic cofactor.